Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interpersonal sensorimotor synchronization therapy plus intranasal oxytocin in autism
2023-505253-41-00Phase 3Withdrawn
- Sponsor
- UZ Leuven
- Start
- Sep 2023
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Autism Spectrum Disorder (ASD) comparing Oxytocin nasal spray with Placebo nasal spray (2 arms). Primary endpoint: Change from baseline in dyadic attunement during screen-based and real-life social interaction paradigms. Planned start Sep 2023; status: withdrawn.
02
Drugs
oxytocin
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on 2023-505253-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505253-41-00.